Thursday, January 23, 2020
The FDA last week approved Novo Nordisk's Ozempic to...
..."reduce the risk of major
adverse cardiovascular events such as heart attack, stroke or death in adults
with type 2 diabetes and known heart disease," an expansion of the drug's
current type 2 diabetes indication. For the treatment of type 2 diabetes,
Ozempic currently holds preferred formulary status for 44% of all covered
lives.
SOURCE: MMIT Analytics, as
of 1/22/20
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment